Research progress in effects of MAGE-A family on gastric cancer.
10.11817/j.issn.1672-7347.2023.220042
- Author:
Qi JIA
1
;
Xiaohong XIAN
2
;
Yangrun LI
2
;
Jiaxin MU
2
;
Zhixing DU
3
Author Information
1. Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou 730000, China. 1223684838@qq.com.
2. Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou 730000, China.
3. Department of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou 730000, China. ery_duzhx@lzu.edu.cn.
- Publication Type:Journal Article
- Keywords:
gastric cancer;
immunotherapy;
melanoma antigen-associated gene-A family;
therapeutic targets
- MeSH:
Male;
Humans;
Stomach Neoplasms/therapy*;
Antigens, Neoplasm/genetics*;
Melanoma;
Immunotherapy;
Prognosis
- From:
Journal of Central South University(Medical Sciences)
2023;48(2):260-267
- CountryChina
- Language:English
-
Abstract:
Gastric cancer (GC) is one of the most common malignant tumors worldwide, and most of the patients are diagnosed at the advanced stage. Most of the treating options are comprehensive treatment, in which immunotherapy plays more and more important role. Melanoma antigen-associated gene-A (MAGE-A) family is a kind of cancer testis antigens. Except in germ cells of testis and trophoblast cells of placenta, MAGE-A family is highly expressed in cancerous tissues and participates in a variety of biological processes, such as cancer cell proliferation, differentiation and metastasis. In addition, cancer testis antigen also possesses good immunogenicity, which can induce humoral and cellular immune responses, is a good target for immunotherapy, and has good application value in the diagnosis, treatment and prognosis of GC. A variety of targeted therapeutic drugs based on MAGE-A are in phase I or II clinical trials, it has good safety and potential clinical application value. With the continuous progress of clinical trials and basic research on MAGE-A targets in GC, it is expected to provide a theoretical basis for clinical transformation and immunotherapy of MAGE-A in the future.
